Regeneron Pharmaceuticals, Inc. (LON:0R2M)
511.39
-2.70 (-0.53%)
At close: Jun 20, 2025
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.03B USD in the quarter ending March 31, 2025, a decrease of -3.70%. This brings the company's revenue in the last twelve months to $14.09B, up 7.52% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.09B
Revenue Growth
+7.52%
P/S Ratio
3.67
Revenue / Employee
$932.46K
Employees
15,106
Market Cap
40.07B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Regeneron Pharmaceuticals News
- 3 days ago - $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
- 3 days ago - Regeneron, Sanofi win FDA label expansion for Dupixent against rare skin disorder - Seeking Alpha
- 4 days ago - Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ
- 4 days ago - Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) - GlobeNewsWire
- 4 days ago - Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid - GlobeNewsWire
- 6 days ago - Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer - Seeking Alpha
- 7 days ago - Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer - Reuters
- 7 days ago - 23andMe’s founder wins bid to regain control of bankrupt DNA testing firm - The Guardian